Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

Sponsor
Solvay Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00349128
Collaborator
(none)
382
51
7.5

Study Details

Study Description

Brief Summary

The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.

Condition or Disease Intervention/Treatment Phase
  • Drug: fenofibrate and metformin combination (drug)
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.
Study Start Date :
Jan 1, 2004

Outcome Measures

Primary Outcome Measures

  1. Change in fasting triglycerides. []

Secondary Outcome Measures

  1. Assessment of lipid and glucose metabolisms. []

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Type 2 diabetes mellitus
Exclusion Criteria:
  • Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose

300 mg/dL - Triglycerides > 500 mg/dL

Contacts and Locations

Locations

Site City State Country Postal Code
1 Site 201 Katowice Poland
2 Site 203 Katowice Poland
3 Site 202 Warszawa Poland
4 Site 204 Zabrze Poland
5 Site 111 Dnipropetrovsk Ukraine
6 Site 113 Dnipropetrovsk Ukraine
7 Site 108 Kharkiv Ukraine
8 Site 109 Kharkiv Ukraine
9 Site 101 Kyiv Ukraine
10 Site 102 Kyiv Ukraine
11 Site 103 Kyiv Ukraine
12 Site 104 Kyiv Ukraine
13 Site 105 Kyiv Ukraine
14 Site 106 Kyiv Ukraine
15 Site 107 Kyiv Ukraine
16 Site 112 Zaporizhya Ukraine
17 Site 35 Acomb United Kingdom
18 Site 21 Atherstone United Kingdom
19 Site 14 Balsall Common United Kingdom
20 Site 32 Bangor United Kingdom
21 Site 23 Barry United Kingdom
22 Site 36 Basingstoke United Kingdom
23 Site 8 Bexhill-on-Sea United Kingdom
24 Site 20 Camberley United Kingdom
25 Site 22 Chesterfield United Kingdom
26 Site 10 Chippenham United Kingdom
27 Site 13 Coventry United Kingdom
28 Site 31 Doncaster United Kingdom
29 Site 15 Downpatrick United Kingdom
30 Site 17 Ely United Kingdom
31 Site 4 Ely United Kingdom
32 Site 11 Fife United Kingdom
33 Site 1 Frome United Kingdom
34 Site 16 Harrow United Kingdom
35 Site 5 Hastings United Kingdom
36 Site 26 Haverfordwest United Kingdom
37 Site 19 Keresley end United Kingdom
38 Site 9 Kingswood United Kingdom
39 Site 25 Newtownabbey United Kingdom
40 Site 33 Northampton United Kingdom
41 Site 28 Odiham United Kingdom
42 Site 3 Paignton United Kingdom
43 Site 12 Petersborough United Kingdom
44 Site 7 Randalstown United Kingdom
45 Site 27 Slough United Kingdom
46 Site 6 Soham United Kingdom
47 Site 2 South Glamorgan United Kingdom
48 Site 34 Stratford on Avon United Kingdom
49 Site 29 Swindon United Kingdom
50 Site 30 Trowbridge United Kingdom
51 Site 18 Yaxley United Kingdom

Sponsors and Collaborators

  • Solvay Pharmaceuticals

Investigators

  • Study Director: Global Clinical Director Solvay, Solvay Pharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00349128
Other Study ID Numbers:
  • C LF23-0121 03 01
First Posted:
Jul 6, 2006
Last Update Posted:
Sep 3, 2007
Last Verified:
Aug 1, 2007

Study Results

No Results Posted as of Sep 3, 2007